Informations générales (source: ClinicalTrials.gov)

NCT02090361 Statut inconnu
Efficacy of Collagen-elastin Dermal Substitute in the Treatment of Loss of Cutaneous Substances With Skin Grafts (MATRIGREFFE)
Interventional
Phase 3
University Hospital, Rouen (Voir sur ClinicalTrials)
juin 2014
juin 2018
29 juin 2024
In reconstructive surgery , most losses of cutaneous substance require the use of a thin skin graft . This technique allows epidermization of the defect by applying a thin layer of autologous epidermis. It does not reconstitute the injured skin. Transplants cause retractile scars, adherent to the deep plan, that may require revision surgery . Since a decade , dermal matrices are mainly used in burned skin centers . The collagen -elastin matrix has the advantage to set up in the same operation that the skin graft and contain elastic fibers , two assets which improve the results of skin grafting. Objective: Evaluation of the clinical efficacy of the addition of a dermal matrix to skin graft on Skin Foldability, at day 360. Methodology: This is a multicenter randomized study (CHU Caen , Amiens, Rouen and Lille) Conduct of the study : The transplant will be performed according to the protocol defined between inter -region surgeons. The implementation of the dermal matrix will be in the same surgical technique as thin skin graft ( group 1 ) or the thin skin graft will be performed alone ( group 2) time . Evaluation Criteria Main : Skin Foldability ( Uf ) assessed grafted site will be compared to the opposite side ungrafted evaluated at Day 360 . Quantitative data will be measured by a cutometer Skin Elasticity Meter 580 (Courage and Khazaba Electronic GmbH). To achieve the main objective, it is planned to compare the ratio between Uf graft site and the opposite healthy site between two groups: skin + matrix graft , or skin graft only. Thus, the Wilcoxon test for independent samples will be used to settle bilateral formulation between the null hypothesis ( there is no difference between the two groups ) and the alternative hypothesis ( there is a difference between the two groups ) . In determining the overall risk of first species to 5% and the power of this test to detect the 90% expected under the alternative hypothesis difference should be the main criterion for evaluating at least 59 patients in each group so 118 patients total. Prospect If the contribution of a dermal matrix in loss of skin substances improves skin pliability and reduces pain , functional and aesthetic sequelae grafts thin skin , the dermal matrix may be proposed as a complementary treatment in these indications.
 Voir le détail

Etablissements

Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données
CHU de Caen - Caen - France Nathalie HANNOUZ, MD En recrutement Contact (sur clinicalTrials)
CHU de Lille - Lille - France Pierre GUERRECHI, MD En recrutement Contact (sur clinicalTrials)
UH Rouen - 76031 - Rouen - France Isabelle AUQUIT-AUCKBUR, Pr En recrutement Contact (sur clinicalTrials)
Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données
CHU d'Amiens - Amien - France Raphael SINNA, Pr En recrutement Contact (sur clinicalTrials)

Critères

Tous
Inclusion Criteria:

- Aged over 18

- Signed informed consent

- Patients with loss of cutaneous substance of at least 15 cm2

- Patient Without bone exposure, vascular, joint or tendon

- Eligibility for surgical treatment by skin graft

- Loss of substance trauma (avulsion, burns) or surgery (skin excision)


- Patient with a chronic wound

- Wound superinfected

- Patient unable for local or general skin graft

- Patient with an old or a recent skin injury strictly contralateral to the graft
site.

- Patient unable to consent